Oppenheimer Maintains Perform on Acadia Pharmaceuticals, Lowers Price Target to $21

Benzinga · 2d ago
Oppenheimer analyst Matthew Hershenhorn maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Perform and lowers the price target from $23 to $21.